Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NCX-4016 NicOx SA.

T W Huizinga1

  • 1Academisch Ziekenhuis Leiden, Department of Rheumatology, Building 1, C4-R, PO Box 9600, 2300 RC Leiden, The Netherlands. Huizinga@Rheumatology.MedFac.LeidenUniv.nl

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.

Arthritis research & therapy·2021
Same author

The value of MRI examination on bilateral hands including proximal interphalangeal joints for disease assessment in patients with early rheumatoid arthritis: a cross-sectional cohort study.

Arthritis research & therapy·2019
Same author

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.

Current medical research and opinion·2019
Same author

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Lupus·2018
Same author

Inflammatory genes TNFα and IL6 display no signs of increased H3K4me3 in circulating monocytes from untreated rheumatoid arthritis patients.

Genes and immunity·2017
Same author

Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.

Annals of the rheumatic diseases·2016
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

NCX-4016, a novel nitric oxide non-steroidal anti-inflammatory drug (NO-NSAID), shows promise for treating thrombosis and inflammation. Early trials indicate good tolerability and potential for improved efficacy and safety compared to aspirin.

Area of Science:

  • Pharmacology
  • Drug Development
  • Inflammation Research

Background:

  • NCX-4016 is a nitric oxide non-steroidal anti-inflammatory drug (NO-NSAID) developed by NicOx.
  • It functions by inhibiting cyclooxygenase and releasing nitric oxide.
  • Potential therapeutic applications include thrombosis, inflammation, and rheumatoid arthritis.

Purpose of the Study:

  • To evaluate the safety and efficacy of NCX-4016.
  • To assess its potential as an oral antithrombotic agent.
  • To compare its tolerability and efficacy against aspirin.

Main Methods:

  • Phase I clinical trials in the UK.
  • Placebo-controlled, double-blind study.
  • In vitro studies on platelet aggregation and adhesion.

Related Experiment Videos

  • In vivo studies in rats to assess biological activity and gastrointestinal safety.

    • Main Results:

    • NCX-4016 demonstrated good tolerability in a completed placebo-controlled, double-blind study.
    • In vitro studies showed interference with platelet aggregation, adhesion, and thromboxane B2 production.
    • Animal studies confirmed biological activity and gastrointestinal safety.
    • Experimental data suggests wider efficacy and tolerability than aspirin.

    Conclusions:

    • NCX-4016 exhibits promising antithrombotic and anti-inflammatory properties.
    • The drug shows potential for improved gastric and renal safety profiles compared to traditional NSAIDs.
    • Further clinical studies are warranted to fully establish its therapeutic potential.